Oestrogen Represses Noggin Expression by Interfering With BMP/Smad Signalling in ER Positive Breast Cancer.
Autor: | Liu M; Cardiff China Medical Research Collaborative, Division of Cancer & Genetics, Cardiff University School of Medicine, Cardiff, U.K.; Department of Breast Surgery, University Hospital of Shandong University of Traditional Chinese Medicine, Jinan, P.R. China., Koo D; Cardiff China Medical Research Collaborative, Division of Cancer & Genetics, Cardiff University School of Medicine, Cardiff, U.K., Jiang WG; Cardiff China Medical Research Collaborative, Division of Cancer & Genetics, Cardiff University School of Medicine, Cardiff, U.K., Ye L; Cardiff China Medical Research Collaborative, Division of Cancer & Genetics, Cardiff University School of Medicine, Cardiff, U.K.; yel@Cardiff.ac.uk. |
---|---|
Jazyk: | angličtina |
Zdroj: | Anticancer research [Anticancer Res] 2024 Aug; Vol. 44 (8), pp. 3355-3364. |
DOI: | 10.21873/anticanres.17156 |
Abstrakt: | Background/aim: As an antagonist of bone morphogenetic protein (BMP), Noggin facilitates osteolytic bone metastases from breast cancer. The present study aimed to further dissect its role in oestrogen receptor (ER) positive breast cancer. Materials and Methods: Noggin expression in ER positive breast cancer cell lines (MCF-7 and T-47D) was determined under conditions of oestrogen deprivation and treatment with 17-β-oestradiol (E Results: Noggin expression was negatively correlated with ERα in breast cancers. Noggin was up-regulated upon oestrogen deprivation, an effect that was eliminated by E Conclusion: Noggin expression can be repressed by oestrogen through inference with the BMP/Smad signalling. Over-expression of Noggin promotes the proliferation of MCF-7 and T-47D cells, contributing to drug resistance. (Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |